Rapport Therapeutics and Tenacia Biotechnology Announce Collaboration to Develop RAP-219 in Greater China

Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotechnology company focused on precision medicines for neurological and psychiatric disorders, and Tenacia Biotechnology, a biopharmaceutical company focused on therapies for neurological disorders, announced a collaboration granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China, including mainland China, Hong Kong, Macau and Taiwan.

RAP-219 is a TARPγ8-specific AMPA receptor negative allosteric modulator currently being developed for neurological and psychiatric indications. The compound is being studied in focal onset seizures (FOS), primary generalized tonic-clonic seizures and bipolar mania.

In September 2025, Rapport reported results from a Phase 2a study of RAP-219 in patients with drug-resistant FOS. The study showed a statistically significant reduction in long electrographic seizure episodes compared with baseline and a reduction in clinical seizures. RAP-219 was generally well tolerated.

Rapport plans to initiate a global Phase 3 program for RAP-219 in focal onset seizures in the second quarter of 2026. As part of the collaboration, Tenacia will lead regional development and commercialization and add Phase 3 clinical trial sites in China.

Under the agreement, Rapport will receive an upfront payment of $20 million and is eligible to receive up to approximately $308 million in development and commercialization milestone payments. Rapport is also eligible for tiered royalties on net sales in Greater China. Tenacia will fund and manage development and commercialization activities in the region, while Rapport retains rights to RAP-219 in the rest of the world.

“Tenacia’s development and commercialization capabilities in Greater China will support the continued development of RAP-219 and expand patient access in the region,” said Abraham N. Ceesay, chief executive officer of Rapport Therapeutics.

“There remains significant unmet need for new treatments for epilepsy and bipolar disorder in Greater China,” said Xiaoxiang Chen, chief executive officer of Tenacia Biotechnology. “We look forward to advancing RAP-219 and supporting its development in the region.”

Goldman Sachs & Co. LLC served as financial advisor to Rapport. Goodwin Procter LLP served as legal advisor to Rapport, while Ropes & Gray served as legal advisor to Tenacia.

About RAP-219
RAP-219 is a clinical-stage small molecule targeting TARPγ8-associated AMPA receptors. TARPγ8 is expressed in selective brain regions, including the hippocampus and neocortex, areas often associated with focal seizures. The compound is being evaluated for focal onset seizures, primary generalized tonic-clonic seizures, bipolar disorder and peripheral neuropathic pain.

About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule therapies for neurological and psychiatric disorders. Its research platform is based on receptor associated proteins (RAPs), which enable targeted approaches to neurological drug development. The company’s pipeline includes programs in epilepsy, bipolar mania and other neurological conditions.

About Tenacia Biotechnology
Tenacia Biotechnology is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders. Founded in 2022 and backed by Bain Capital, the company focuses on research, development and commercialization of treatments addressing unmet needs in neuroscience.